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Abstract
Introduction: Severe hypoglycemia (blood glucose concentration (BG) < 40 mg/dL) is independently associated
with an increased risk of mortality in critically ill patients. The association of milder hypoglycemia (BG < 70 mg/dL)
with mortality is less clear.
Methods: Prospectively collected data from two observational cohorts in the USA and in The Netherlands, and
from the prospective GLUCONTROL trial were analyzed. Hospital mortality was the primary endpoint.
Results: We analyzed data from 6,240 patients: 3,263 admitted to Stamford Hospital (ST), 2,063 admitted to three
institutions in The Netherlands (NL) and 914 who participated in the GLUCONTROL trial (GL). The percentage of
patients with hypoglycemia varied from 18% to 65% among the different cohorts. Patients with hypoglycemia
experienced higher mortality than did those without hypoglycemia even after stratification by severity of illness,
diagnostic category, diabetic status, mean BG during intensive care unit (ICU) admission and coefficient of variation
(CV) as a reflection of glycemic variability. The relative risk (RR, 95% confidence interval) of mortality associated with
minimum BG < 40, 40 to 54 and 55 to 69 mg/dL compared to patients with minimum BG 80 to 109 mg/dL was
3.55 (3.02 to 4.17), 2.70 (2.31 to 3.14) and 2.18 (1.87 to 2.53), respectively (all P < 0.0001). The RR of mortality
associated with any hypoglycemia < 70 mg/dL was 3.28 (2.78 to 3.87) (P < 0.0001), 1.30 (1.12 to 1.50) (P = 0.0005)
and 2.11 (1.62 to 2.74) (P < 0.0001) for the ST, NL and GL cohorts, respectively. Multivariate regression analysis
demonstrated that minimum BG < 70 mg/dL, 40 to 69 mg/dL and < 40 mg/dL were independently associated
with increased risk of mortality for the entire cohort of 6,240 patients (odds ratio (OR) (95% confidence interval (CI))
1.78 (1.39 to 2.27) P < 0.0001), 1.29 (1.11 to 1.51) P = 0.0011 and 1.87 (1.46 to 2.40) P < 0.0001) respectively.
Conclusions: Mild hypoglycemia was associated with a significantly increased risk of mortality in an international
cohort of critically ill patients. Efforts to reduce the occurrence of hypoglycemia in critically ill patients may reduce
mortality
Introduction
Hyperglycemia occurs commonly in critically ill patients
and is strongly associated with increased risk of mortal-
ity [1-3]. Interventional trials designed to treat even
moderate degrees of hyperglycemia with insulin have
met with mixed success. A landmark single-center trial
among a cohort of surgical intensive care unit (ICU)
patients resulted in substantial reductions in mortality
and morbidity in the treated patients [4]. Three years
later a large observational study in a heterogeneous
population of ICU patients reached a similar conclusion
[5]. However, in the second Leuven trial of intensive
insulin therapy (IIT), conducted in a cohort of medical
patients, patients in the interventional arm did not
demonstrate reduced mortality, but did have shorter
ICU length of stay and duration of mechanical ventila-
tion [6]. Subsequent trials of IIT were stopped prema-
turely due to high rates of hypoglycemia and protocol
violations [7,8] or demonstrated higher mortality among
the intensively treated cohort [9]. In fact, the second
Leuven trial was the first investigation to identify an
association between severe hypoglycemia (BG < 40 mg/
dL) and mortality [6].
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as blood glucose concentration (BG) < 40 mg/dL and
identified as having an independent association with
mortality in several large observational cohorts [10-12],
was a key feature that distinguished the first two investi-
gations [4,5] from those that followed [6-9]. The Leuven
investigators subsequently pooled data from their surgi-
cal [4] and medical [6] trials and used multivariate ana-
lysis to confirm that severe hypoglycemia had a strong
and independent association with mortality [13]. A
recent large observational cohort study suggested that
even mild levels of hypoglycemia, defined as BG < 72
mg/dL, were associated with increased risk of death
among critically ill patients [14]. Consistently, the
recently revised standards of medical care in diabetes
used a threshold BG of 70 mg/dl to define hypoglycemia
[15].
The purpose of this study was to evaluate the associa-
tion of hypoglycemia, defined as BG < 70 mg/dL, with
mortality. We hypothesized that (1) hypoglycemia (BG <
70 mg/dL) was associated with increased risk of mortal-
ity, and (2) that a glycemic management strategy that
tolerated brief periods of mild hypoglycemia and cor-
rected these events without creating marked glycemic
excursions would demonstrate a weaker association with
mortality than would protocols that avoided and treated
mild hypoglycemia more vigorously. We had the unique
opportunity to analyze a large and diverse group of criti-
cally ill patients in an international collaboration, includ-
ing a large single-center cohort from 1 ICU in the
United States of America, a multicenter cohort from 3
ICUs from The Netherlands, and 21 ICUs from Europe
and Israel that participated in the GLUCONTROL trial,
a multicenter randomized controlled trial of IIT [8].
Materials and methods
Settings
The adult ICU of Stamford Hospital (Stamford, CT,
USA) is a 16-bed unit that treats a heterogeneous popu-
lation of medical, surgical and trauma patients. Medical
and surgical house staff, closely supervised by a team of
intensivists, deliver care.
The adult ICUs of the three hospitals in The Nether-
lands (Gelre Hospital, Apeldoorn, The Netherlands; Ter-
gooi Hospitals, Hilversum, The Netherlands; Medical
Center Haaglanden, The Hague, The Netherlands) are a
10-bed, 9-bed and 18-bed unit, respectively, which treat
a heterogeneous population of medical, surgical and
trauma patients. A team of intensivists delivers care in a
closed-format setting.
Twenty-one adult ICUs from 19 different hospitals in
seven countries in Europe and Israel participated in the
GLUCONTROL trial [8] The number of ICU beds of
the participating units ranged from 5 to 44 (median 12).
Patients
The patient cohort in Stamford (ST) included 3,263
patients admitted to the ICU between 12 January 2007
and 30 April 2010, who had at least three BG values
obtained during their ICU stay. Forty-one patients
admitted during this period with a diagnosis of diabetic
ketoacidosis or hyperosmolar nonketotic coma were
excluded from the present analysis.
The patient cohort in The Netherlands (NL) included
2,063 patients admitted to the three ICUs between 1
January 2007 and 29 December 2009, who had at least
three BG values obtained during their ICU stay: 1,098
patients, admitted between 1 January 2007 and 31 Janu-
ary 2008 were subjected to a “loose” IIT guideline; 965
patients admitted between 1 February 2008 and 29
December 2009 were subjected to a “strict” IIT guideline
(see below for details on “loose” and “strict” IIT). Per
protocol, patients admitted during this period with a
diagnosis of diabetic ketoacidosis or hyperosmolar non-
ketotic coma were not subjected to treatment according
to the guidelines.
The patient cohort in the GLUCONTROL trial (GL)
included 914 patients with at least three BG values; the
other 164 patients (those with fewer than three BG
recorded) were evenly distributed between the intensive
(GL-IIT) and intermediate glucose control groups (GL-
C).
Glycemic control and blood glucose monitoring
The glycemic target in Stamford during the period of
the investigation was 80 to 125 mg/dL. Details of the
protocol have been published previously [16] (and are
available as Additional file 1). Most of the BG measure-
ments (85%) were made using bedside glucometers
(Accu-Chek Inform, Indianapolis, IN, USA) and capil-
lary or venous blood; the remainder were performed in
the central laboratory using a Siemens Advia 1800 ana-
lyzer (Siemens Corporation US, Washington, DC, USA)
or in the ICU using a GEM4000 point of care analyzer
(Instrument Laboratory, Lexington, MA, USA).
Patients in the NL cohort were treated with loose or
strict IIT. With loose glucose control, the three partici-
pating ICUs followed the 2004 Surviving Sepsis Cam-
paign Guidelines [17], and aimed for a BG < 150 mg/dL.
Insulin dose and route of administration (either intrave-
nous or subcutaneous), and timing and type of BG mea-
surement (either using capillary or arterial blood, at the
bedside or in a central laboratory) were loosely defined
in the guidelines in use. ICUs nurses practiced blood
glucose control. With strict IIT, the ICUs followed an
adjusted Leuven guideline with a glycemic target range
of 80 to 110 mg/dL [18]; administration of insulin was
intravenous at all times, and BG measurements were
performed at the bedside. Notably, while the protocol
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from 60 to 80 mg/dL if they were short in duration. In
such case, insulin infusion was stopped. Small boluses of
dextrose were given only in case of severe hypoglycemia.
Blood glucose control required a high level of intuitive
decision-making. All BG measurements were made
using bedside glucometers (AccuChek Inform, Almere,
The Netherlands) and arterial blood; capillary blood was
never used.
In the GLUCONTROL trial, patients were randomized
to IIT (target BG: 80 to 110 mg/dl) or intermediate glu-
cose control (target BG 140 to 180 mg/dl), using an
insulin protocol ([8], and available as Additional file 2).
BG measurements were performed on arterial or central
venous samples when a catheter was in place and a
blood gas analyzer was used preferentially. Capillary
samples and a specific glucometer (Accu to Check
Inform, Roche Diagnostics, Mannheim, Germany) were
allowed.
Data collected
In Stamford, data were abstracted from the ICU’sc o m -
prehensive clinical database, including prospective col-
lection of admission diagnosis, demographic information
and calculation of the Acute Physiology and Chronic
Health Evaluation II (APACHE II) scores. The database
is linked to the hospital’s clinical information system to
retrieve glucose values and the patient’s hospital dis-
charge status. Diabetic status was determined prospec-
tively based on all available clinical information for
every patient.
The Dutch centers’ data were abstracted from the
National Intensive Care Evaluation (NICE) database,
maintained by the NICE Foundation [19], including pro-
spective collection of admission diagnosis, demographic
information and calculation of the APACHE II scores.
The database was linked to the hospital’sc l i n i c a li n f o r -
mation system to retrieve BG.
For the GL cohort, the data were abstracted from the
original database recorded by the study participants. An
independent biostatistician managed the web-based cen-
tral database.
Statistical analysis
Hypoglycemia was defined as BG < 70 mg/dL. Severe
hypoglycemia was defined as BG < 40 mg/dL. Addi-
tional stratification included bands of a minimum BG of
40 to 54, 55 to 69, 70 to 79, 80 to 109 and ≥ 110 mg/
dL We calculated the relative risk of mortality asso-
ciated with increments of hypoglycemia compared to
patients with a minimum BG of 80 to 109 mg/dL. Addi-
tional analyses stratified patients by mean BG during
ICU stay using increments of 80 to 110 mg/dL, 110 to
140 mg/dL, 140 to 180 mg/dL and ≥ 180 mg/dL, as
well as by severity of illness, using APACHE II scores,
and by diabetic status and diagnostic category. We also
calculated the coefficient of variation (CV) for each
patient, defined as standard deviation of the mean BG/
mean BG. Multivariate analysis to assess the indepen-
dent association of hypoglycemia with mortality
included the following parameters found to be statisti-
cally significant at P < 0.10 on univariate analysis: age,
modified APACHE II score (age component deleted, in
order to avoid colinearity with age in the multivariate
analysis: age 45 to 54 two points; age 55 to 64 three
points; age 65 to 74 five points; age ≥ 75 six points),
ICU LOS, diagnostic category on admission to the ICU
(medical vs. surgical), mechanical ventilation, mean BG
and CV. Diabetes was not associated with mortality on
univariate analysis and, therefore, was not entered into
the multivariate model.
Continuous data were presented as median (interquar-
tile range), and compared using the Mann Whitney rank
sum test; all chosen parameters were not normally dis-
tributed. Ordinal data were presented as percentages
and compared using the Chi square test. Mortality was
defined throughout as hospital- (that is, not ICU-) mor-
tality. Statistical analysis was performed using the Med-
Calc statistical package version 10.1.1.6.0 (MedCalc
software, Broekstraat 52, 9030 Mariakerke, Belgium). A
P- value of < 0.05 was considered statistically significant.
The Stamford Hospital institutional review board
approved this investigation.
The GLUCONTROL trial was approved by each insti-
tutional review board of the 21 participating hospitals.
Patients, or their designated surrogates, participating in
the trial gave informed consent.
Approval to conduct the study was obtained from the
medical ethics committees of the three centers of the
Academic Medical Center in The Netherlands, which
waived the requirement for individual patient-level
consent.
Results
Cohort characteristics
Table 1 illustrates differences in clinical characteristics,
outcomes and frequently used metrics of glycemic con-
trol among patients in the three cohorts, as well as
aggregated data for the entire population of 6,240
patients. The percentage of patients with hypoglycemia
varied considerably, as did mean glucose level, glycemic
variability and mortality. Table 2 details the different
outcomes of patients with and without hypoglycemia.
For the entire cohort of 6,240, patients with hypoglyce-
mia were older, had higher APACHE II scores, ICU
LOS and mortality and also had higher indices of glyce-
mic variability and lower mean BG during ICU stay (all
comparisons P < 0.0001).
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Table 3 demonstrates for the entire cohort of 6,240
patients increased relative risk (RR) of mortality for
patients with minimum BG < 40, 40 to 54, 55 to 69,
70 to 79 compared to those with a minimum BG of 80
to 109 mg/dL and Figure 1 stratifies these results by
subpopulation. Increasing severity of hypoglycemia was
consistently associated with increased risk of mortality.
The RR (95% CI) for mortality associated with hypo-
glycemia (BG < 70 mg/dL) in ST patients was 3.28
(2.78 to 3.87) P < 0.0001; for NL patients in the
“loose” and “strict” cohorts it was 1.53 (1.27 to 1.86) P
< 0.0001 and 1.10 (0.87 to 1.38) P = 0.4288, respec-
tively; and for patients in the GL cohort it was 2.11
(1.62 to 2.74). Figure 2 stratifies this analysis by sever-
ity of illness. The association between mortality and
mild hypoglycemia is strongly demonstrated for
patients with a mild to moderate (APACHE II score <
15) and moderately severe (APACHE II score 15 to 24)
d i s e a s eb u tb l u n t e df o rt h o s ew i t hv e r ys e v e r ed i s e a s e
(APACHE II score > 24).
Association between hypoglycemia and mortality,
stratified by clinical characteristics of patients
Table 4 demonstrates that patients with hypoglycemia
sustained higher mortality than did those without hypo-
glycemia, regardless of diagnostic category, diabetic sta-
tus, ICU LOS and frequency of BG measurements.
Table 5 displays the results of multivariate regression
analysis of the association between hypoglycemia and
mortality for patients with these clinical characteristics,
as well as the independent association of mortality asso-
ciated with BG < 70 mg/dL, BG 40 to 69 mg/dL and
BG < 40 mg/dL.
Mortality associated with number of hypoglycemic events
Among 4,906 patients with no or one episode of hypo-
glycemia, multivariate analysis demonstrated that a sin-
gle episode of hypoglycemia was independently
Table 1 Characteristics of the patient cohorts
ALL ST NL-L NL-S GL-C GL-IIT
Demographics and outcomes
Number 6,240 3,263 1,098 965 460 454
Age 68 (54 to 78) 68 (53 to 80) 69 (57 to 78) 68 (56 to 78) 65 (53 to 74) 65 (51 to 74)
DM (%) 20.4 20.5 N/A N/A 22.6 17.2
Diagnostic category (%)
Medical 55.2 54.1 64.1 63.2 39.9 40.4
Surgical/Trauma 44.8 45.9 35.9 36.8 60.1 59.6
Mechanical ventilation (%) 45.8 35.4 N/A N/A 84.2 82.0
ICU LOS 2.5 (1.1 to 5.7) 1.5 (0.9 to 3.1) 3.0 (1.8 to 6.9) 3.0 (1.7 to 6.3) 6.0 (3.0 to 13.0) 6.0 (3.0 to 12.5)
APACHE II score 16 (11 to 22) 14 (10 to 21) 19.7 (8.2) 19.4 (8.3) 15 (11 to 21) 15 (11 to 21)
Mortality (%) 19.2 14.2 27.5 26.0 17.8 22.9
Glucose control parameters
Number of BG measurements per
patient
18 (9 to 47) 15 (8 to 34) 17 (7 to 38) 29 (12 to 69) 29 (12 to 74) 37 (15 to 93)
Number of BG measurements per
day*
8.7 (5.7 to 10.5) 9.3 (8.0 to 11.3) 5.1 (3.6 to 7.6) 9.8 (6.8 to 12.1) 4.5 (3.2 to 6.7) 5.6 (3.8 to 9.0)
Mean (mg/dL) 124.4 (112.2 to
140.7)
124.0 (112.0 to
138.0)
127.7 (116.4 to
145.0)
117.9 (107.0 to
137.0)
146.3 (128.1 to
164.6)
118.5 (109.3 to
130.3)
CV (%) 23.8 (16.7 to
32.6)
21.0 (14.8 to
28.5)
26.9 (18.8 to
35.2)
31.8 (23.8 to
40.8)
20.7 (15.4 to
26.2)
26.2 (20.3 to
33.1)
SD (mg/dL) 29.5 (20.0 to
42.6)
25.9 (17.7 to
37.5)
33.8 (23.6 to
49.4)
37.1 (27.3 to
50.3)
29.3 (19.9 to
41.7)
30.5 (22.7 to
42.1)
Percentage of patients with
hypoglycemia
< 40 mg/dL 6.7 2.9 8.8 18.1 2.4 9.5
40 to 54 mg/dL 12.6 8.4 13.6 25.2 3.9 23.1
55 to 69 mg/dL 17.7 14.9 19.3 21.6 11.5 31.3
< 70 mg/dL 37.0 26.2 41.7 64.9 17.8 63.9
APACHE II, Acute Physiology and Chronic Health Evaluation II disease classification system; BG, blood glucose; CV, coefficient of variation; DM, diabetes mellitus;
GL-C, patients in the control arm of the GLUCONTROL trial; GL-IIT, patients in the intervention arm of the GLUCONTROL trial; LOS, length of stay (days); NL-L,
Netherlands “loose” cohort; NL-S, Netherlands “strict” cohort; SD, standard deviation; ST, Stamford cohort.
*Calculated as (mean number of BG tests/mean ICU LOS). Data expressed as median (interquartile range), or percentages
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1.31 (1.06 to 1.62) P = 0.0121. Among 5,535 patients
with up to three episodes of hypoglycemia, multivariate
analysis demonstrated that hypoglycemia was indepen-
dently associated with incre a s e dr i s ko fm o r t a l i t y :O R
(95% CI) 1.35 (1.14 to 1.61) P = 0.0007 Among the
entire cohort of 6,240 patients, patients with four or
more episodes of hypoglycemia had OR for mortality:
1.49 (1.20 to 1.83) P = 0.0002 (compared to patients
without hypoglycemia).
Association between hypoglycemia and mortality,
stratified by mean BG concentration and coefficient of
variation
Figure 3 displays mortality stratified by bands of mean
BG during ICU stay: < 80 mg/dL, 80 to 110 mg/dL, 110
to 140 mg/dL, 140 to 180 mg/dL and ≥ 180 mg/dL, in
patients with and without hypoglycemia. Among
patients with mean BG 80 to 110 mg/dL, hypoglycemia
was associated with a 4-fold increase in mortality; the
“hypoglycemia penalty” was 2.8-fold for patients with
mean BG 110 to 140 and 2-fold for patients with a
mean BG of 140 to 180 mg/dL. Among patients with
CV < 15%, 15 to 30% and ≥ 30% mortality was higher in
patients with hypoglycemia than in patients without
hypoglycemia: 13.3% vs. 6.9% (P = 0.3216), 26.4% vs.
Table 2 Characteristics of patients with hypoglycemia and patients without hypoglycemia
ALL ST NL GL
HYPO NON HYPO NON HYPO NON HYPO NON
Demographics and
outcomes
Number 2,309 3,921 857 2,406 1,084 979 372 542
Age (years) 70 (57 to 79) 66 (52 to 71) 75 (60 to 83) 66 (51 to 78) 69 (58 to 78) 68 (55 to 78) 66 (51 to 75) 65 (52 to 73)
DM (%) 27.3 17.5 29.6 17.2 N/A N/A 22.5 18.7
Diagnostic Category (%)
Medical 64.5 49.8 69.7 48.5 65.5 61.7 48.7 33.4
Surgical/Trauma 35.5 50.2 30.3 51.5 34.5 38.3 51.3 66.6
Mechanical ventilation 63.3 38.5 55.0 28.5 N/A N/A 82.6 83.5
ICU Length of Stay 5.0 (2.2 to
10.5)
1.8 (1.0 to
3.3)
3.0 (1.4 to
7.1)
1.2 (0.8 to
2.3)
5.2 (2.6 to
10.3)
2.0 (1.3 to
3.2)
9( 5t o1 7 ) 5( 3t o9 )
APACHE II score 20 (14 to 26) 14 (10 to 19) 21.1 (9.3) 14.2 (8.1) 21.2 (7.8) 17.8 (8.4) 18.7 (7.5) 15.3 (6.5)
Mortality (%) 29.6 13.1 29.1 8.9
1 30.1 23.2 29.6 14.0
Glucose control
parameters
Number of BG
measurements per patient
45 (21 to 97) 11 (7 to 24) 35 (16 to 90) 11 (7 to 23) 47 (24 to 92) 9 (5 to 18) 69 (29 to
136)
20 (10 to 48)
Number of BG
measurements per day*
9.5 (7.2 to
11.9)
8.0 (5.0 to
10.0)
11.7 9.2 9.0 4.5 7.7 4.0
Mean (mg/dL)^ 118.3 (108.1
to 132.5)
128.1 (115.3
to 144.4)
120.3 (108.4
to 133.9)
125.4 (113.4
to 138.6)
1
116.9 (107.5
to 129.9)
131.9 (119.2
to 152.6)
119.1 (109.0
to 136.3)
137.5 (121.0
to 158.4)
CV (%) 31.6 (25.0 to
40.0)
19.2 (13.7 to
26.1)
29.3 (23.1 to
38.2)
18.4 (13.0 to
24.6)
34.2 (23.0 to
42.4)
21.7 (15.0 to
30.2)
27.7 (22.6 to
35.5)
20.2 (15.2 to
25.8)
SD (mg/dL) 24.8 (16.7 to
36.0)
37.6 (28.9 to
50.4)
34.9 (26.2 to
48.8)
22.7 (15.4 to
32.5)
40.2 (31.2 to
54.1)
28.1 (18.8 to
44.5)
34.8 (25.7 to
46.6)
27.5 (19.1 to
38.8)
*Calculated as (mean number of BG tests/mean ICU LOS)
^These values represent the median (IQR) of the individual patients’ mean BG
Data expressed as median (interquartile range), or percentages
APACHE II, Acute Physiology and Chronic Health Evaluation II disease classification system; BG, blood glucose; CV, coefficient of variation; DM, diabetes mellitus;
GL, GLUCONTROL cohort; HYPO, hypoglycemia (BG < 70 mg/dL); LOS, length of stay (days); NL, Netherlands cohort; NON, no hypoglycemia; SD, standard
deviation; ST, Stamford cohort.
Table 3 Relative risk of mortality: comparison to patients
with a minimum BG of 80 to 110 mg/dL
Minimum BG (mg/
dL)
Number of
patients
RR (95% CI) P-value
< 40 421 3.55 (3.02 to
4.17)
<
0.0001
40 to 55 789 2.70 (2.31 to
3.14)
<
0.0001
55 to 70 1,103 2.18 (1.87 to
2.53)
<
0.0001
70 to 80 854 1.43 (1.18 to
1.73)
0.0002
80 to 110 2,383 Reference
≥ 110 690 1.35 (1.10 to
1.66)
0.0046
BG, blood glucose; CI, confidence interval; RR, relative risk
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Finally, Figure 4 presents unadjusted mortality rates for
patients with differing mean blood glucose, differing
coefficient of variation of blood glucose and presence or
absence of hypoglycemia. The highest crude mortality
rates were observed in patients with higher mean blood
glucose and coefficient of variation of blood glucose
who experience hypoglycemia. Patients with hypoglyce-
mia, high glycemic variability and high mean BG sus-
tained 7.5-fold higher mortality than did those with low
glycemic variability, low mean BG and no hypoglycemia.
Discussion
This study examined the relationship between hypoglyce-
mia occurring during ICU stay and hospital mortality in
three cohorts of patients. The salient finding is that even
a single episode of mild hypoglycemia, defined as BG <
70 mg/dL, was associated with increased risk of mortality.
A major strength of this investigation includes the nature
of the aggregated patient cohort, involving patients from
different countries, with varying severities of illness and
I C UL O S ,t r e a t e di nI C U ’s using different glycemic tar-
gets, measurement technologies and glycemic manage-
ment protocols. Notably, the association between
hypoglycemia and mortality was different among cohorts
with different strategies of glucose control. The highest
relative risk for mortality was seen in the cohort with the
lowest rates of hypoglycemia while the lowest risk for
mortality was seen in the cohort in whom short episodes
of mild hypoglycemia were accepted as part of the guide-
line for IIT. The association between hypoglycemia and
mortality was independent of diagnostic category and
diabetic status and was seen predominantly in patients
with mild to moderate and moderate to severe disease on
presentation to the ICU, reflected by APACHE II scores
0 to 14 and 15 to 24 respectively. Finally, the association
of hypoglycemia with mortality was cumulative to the
associations of hyperglycemia and increased glycemic
variability with mortality [20].
This investigation expands upon earlier work studying
the association of hypoglycemia with mortality in the
critically ill. It is notable that the investigators of the
first prospective randomized controlled trial of IIT [4]
and a subsequent confirmatory before and after investi-
gation [5] stated that severe hypoglycemia (SH, defined
as BG < 40 mg/dL) did not have an independent effect
on mortality. However, a subsequent pooled analysis of
the two Leuven trials [13] determined that the OR for
m o r t a l i t ya s s o c i a t e dw i t has i n g l ee p i s o d eo fS Hw a s
3.23 (2.25 to 4.64) (P < 0.0001). This compares to the
Figure 1 Relationship between minimum BG during ICU stay
and mortality, stratified by subpopulation. BG, blood glucose;
GL-C, GLUCONTROL-control arm; GL-I, GLUCONTROL-intensive arm;
NL-L, Netherlands-"loose"; NL-S, Netherlands-"strict"; ST, Stamford.
Figure 2 Relationship between minimum BG during ICU stay
and mortality, stratified by APACHE II score. APACHE II, Acute
Physiology and Chronic Health Evaluation II disease classification
system; BG, blood glucose.
Table 4 Mortality percentages of patients with
hypoglycemia and without hypoglycemia, stratified by
different clinical characteristics
Characteristic Hypoglycemia No hypoglycemia P-value
Diagnostic category
Medical 33.9 19.2 < 0.0001
Surgical/trauma 21.8 7.1 < 0.0001
Diabetes 27.2 10.5 < 0.0001
No diabetes 30.0 9.7 < 0.0001
ICU LOS
< 3 days 28.3 11.4 < 0.0001
3 to 7 days 29.0 14.6 < 0.0001
> 7 days 30.6 22.2 0.0024
Frequency of BG tests
< 6/day 25.2 14.4 < 0.0001
6 to 9/day 31.3 12.1 < 0.0001
> 9/day 29.9 13.0 < 0.0001
BG, blood glucose; LOS, length of stay
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reported from two large observational series, 2.28 (1.41
to 3.70) in a cohort of 5,365 mixed medical-surgical
patients from a single ICU in the USA [10] and 2.6 (2.1
to 3.2) in a cohort of 66,184 patients admitted to 24
Australian ICUs [11]. Recently, Egi et al. investigated
the relationship between milder degrees of hypoglycemia
and mortality in a population of 4,946 patients admitted
to two Australian ICUs with glycemic targets of 108 to
180 mg/dL [14]. Multivariatea n a l y s i sr e v e a l e dt h a t
patients with a minimum BG of 54 to 63 mg/dL had
significantly higher risk of mortality than did those with
a minimum BG of 72 to 81 mg/dL, OR 1.93 (1.27 to
2.95) (P = 0.002) - as well as significantly higher risk of
infection - OR 2.16 (1.17 to 3.99) (P =0 . 0 1 ) .T h ef i n d -
ings of the current investigation corroborate the
association of mild hypoglycemia with increased risk of
mortality in critically ill patients demonstrated in the
study by Egi and coworkers.
The strengths of the current investigation include, in
part, the diverse nature of the different patient popula-
tions and the breadth of the dataset used for analysis.
This international collaboration comprises large, well
described observational cohorts from one ICU in the
USA and three ICUs in The Netherlands, as well as the
21 ICUs participating in one of the major randomized
controlled trials of intensive insulin therapy [8], increas-
ing the generalizability of its findings. We acknowledge
several limitations in the dataset used for this analysis.
The use of bedside glucometers in a percentage of
patients in all three cohorts and capillary fingerstick
blood in a percentage of the patients in the ST and GL
c o h o r t si sap o t e n t i a ll i m i t a t i o na st h i st e c h n o l o g yh a s
Table 5 Multivariate analysis
Minimum BG < 40 mg/dL Minimum BG 40 to 69 mg/dL Minimum BG < 70 mg/dL
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Entire cohort
1
(n = 6,240)
1.49 (1.14 to 1.94) 0.0031 1.17 (0.99 to 1.38) 0.0557 1.47 (1.22 to 1.78) < 0.0001
No diabetes
2
(n = 3,326)
2.42 (1.42 to 4.10) 0.0011 1.33 (1.02 to 1.75) 0.0370 1.65 (1.24 to 2.19) 0.0005
Diabetes
2
(n = 850)
2.37 (1.12 to 5.01) 0.0236 1.58 (0.99 to 2.52) 0.0549 2.48 (1.48 to 4.15) 0.0005
Medical admission
1
(n = 3,441)
1.44 (1.02 to 2.03) 0.0395 1.06 (0.85 to 1.32) 0.6165 1.28 (1.00 to 1.63) 0.0472
Surgical/trauma admission
1 (n = 2,787) 1.59 (1.05 to 2.40) 0.0283 1.34 (1.04 to 1.72) 0.0220 1.77 (1.34 to 2.34) < 0.0001
Multivariate model includes age; modified APACHE II score (age component deleted); CV; ICU LOS; mean BG; medical vs. surgical/trauma admission; mechanical
ventilation (as indicated)
1 Does not include mechanical ventilation in the model
2 Excludes NL patients (for whom MV and diabetes data not available); includes MV in the model
APACHE II, Acute Physiology and Chronic Health Evaluation II disease classification system; BG, blood glucose; CV, coefficient of variation; LOS, length of stay; NL,
Netherlands cohort; OR, odds ratio
Figure 3 Relationship of mean blood glucose-mortality,
stratified by presence or absence of hypoglycemia. There were
32 patients with mean BG < 80 mg/dL, 28 with hypoglycemia
(51.9% mortality) and 1 without hypoglycemia (25% mortality). BG,
blood glucose; HYPO; hypoglycemia BG < 70 mg/dL.
Figure 4 Association of mortality with disturbances in the
three domains of glycemic control. There were no patients with
Mean BG > 140 mg/dL and CV < 15%. BG, blood glucose; CV,
coefficient of variation; HYPO, hypoglycemia BG < 70 mg/dL.
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Page 7 of 10been associated with analytic inaccuracies in critically ill
populations [21-23]. Nevertheless, this measurement
technology reflects “real world” practices. Moreover, any
“scatter” of the data induced by a measurement technol-
ogy less accurate than a central laboratory analyzer
would serve to “dampen” the signal of the association of
hypoglycemia and mortality in this population. It is
notable that Egi et al. [ 1 4 ] ,i nas t u d yt h a ts o l e l yu s e d
arterial blood gas analyzersf o rg l u c o s em e a s u r e m e n t ,
identified a threshold for the association between hypo-
glycemia and mortality that was similar to that seen in
our investigation. While the manual and intermittent
nature of monitoring BG in all three cohorts likely led
to an incomplete accounting of all the hypoglycemia
that occurred in the patients studied, due to the nursing
time required for compliance with even hourly BG [24],
it is likely that the size of the combined cohort was suf-
ficient to examine the endpoints chosen. The absence of
information about nutritional support, insulin treatment
and glycemic control after ICU stay are additional lim-
itations in the dataset used for this analysis. Finally,
there are no data available to evaluate the relationship
between the timing of the hypoglycemic events and
death, or the specific causes of death for patients in the
three cohorts.
There are some possible links between hypoglycemia
and worsened outcome or complicated course of criti-
cal illness [25]. First, the physiological mechanisms
triggered by hypoglycemia are commonly impaired
during critical illness. These include the inhibition of
insulin release, typically occurring when BG is lower
than 80 mg/dl [26]; an increased release of glucagon,
epinephrine and growth hormone when BG is lower
than 65 mg/dl and increased release of cortisol when
BG is lower than 55 mg/dl [27]. During critical illness,
exogenous insulin is infused and the levels of glucagon,
epinephrine, cortisol and growth hormone are typically
already elevated. Second, large swings in BG, as
observed when hypoglycemia is aggressively treated
with a large amount of intravenous glucose, may be
associated with cellular damages [28]. Unfortunately,
data detailing the amount of glucose given to treat
hypoglycemia and the neurological status of the
patients in our three cohorts were not available. Third,
the detrimental effects of hypoglycemia are well docu-
mented in the brain. Indeed, glucose is the preferential
energetic substrate in the brain. The absence of cere-
bral stores of glucose and the diffusive character of
transport imply that the glucose concentration in neu-
rons and glial cells is entirely determined by BG [29].
Therefore, brain injured patients are at higher risk of
hypoglycemia-related damage; conversely, hypoglyce-
mia also induces brain dysfunction even in patients
without prior cerebral compromise.
This study has a number of important clinical implica-
tions. While earlier investigations detailed the indepen-
dent association of severe hypoglycemia with increased
risk of mortality in critically ill patients [10-13], the data
from the current work suggest strongly that milder
degrees of hypoglycemia are also associated with harm.
Moreover, mild hypoglycemia was associated with
increased risk of mortality among patients admitted
with medical as well as surgical diagnoses, among
patients with diabetes and those without, and among
patients with mild-moderate disease and moderate-
severe disease, as reflected by APACHE II score (but
not among patients with APACHE II scores ≥ 25, in
whom the severity of illness may have overwhelmed the
independent impact of hypoglycemia).
Interestingly, the signal for harm varied in the three
cohorts. The relative risk of mortality associated with
hypoglycemia was strongest for patients in the ST
cohort, intermediate for patients in the GL cohort, and
smallest for those in the NL cohort, inversely related to
the prevalence of hypoglycemia in the three populations
of patients. One explanation of this finding is the differ-
ent distribution of severity of illness in the cohorts, as
reflected by APACHE II scores. More patients in the
NL cohort had APACHE II scores ≥ 25 than did
patients in the ST and GL cohort. Figure 2 demon-
strates that there was no association between hypoglyce-
mia and mortality among patients in these groups;
perhaps the severity of illness lowered the sensitivity of
the association of hypoglycemia with increased risk of
mortality. In addition, patients in the “strict” IIT cohort
in the NL, with a glycemic target of euglycemia, were
treated using a guideline that allowed brief excursions
into the 60 to 80 mg/dL, resulting in a higher rate of
hypoglycemia than was seen in the other cohorts. The
IIT guideline used for the NL cohort also allowed
patients to gradually recover from hypoglycemia, avoid-
ing the administration of quantities of dextrose that
might lead to sharp spikes in glucose levels and, conse-
quently, excessive glucose variability, recently identified
as having an independent association with increased risk
of mortality in critically ill patients [13,30-32]. This
practice could be a second reason that the sensitivity of
the association between hypoglycemia and mortality was
lowered in the NL-S cohort. Additional differences
between the NL-L and NL-S cohorts included the exclu-
sive use of arterial blood for measurement of BG in the
IIT group, and significantly higher glycemic variability,
as reflected by CV and SD, in the NL-S cohort. Thus,
any future evaluations of the association of hypoglyce-
mia with mortality in critically ill populations may bene-
fit from an analysis of the severity of illness, the
prevalence and practice of treating hypoglycemia, as
well as the glycemic management protocol employed.
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recent study of a U-shaped curve relating mean BG to
mortality in critically ill patients [33]. The lowest mor-
tality was associated with a mean BG of 80 to 110 mg/
dL and 110 to 140 mg/dL during ICU stay. Patients
with hypoglycemia in these two bands of mean BG had
very similar mortality, but 4.3 and 2.6 times the rate of
mortality as those without hypoglycemia, respectively.
Higher bands of mean BG were associated with even
higher rates of mortality, both for patients with and
without hypoglycemia. These observations are parallel to
some of the key findings of the major interventional
trials of intensive insulin therapy. The sharply higher
mortality observed in patients with a mean BG of 80 to
110 mg/dL and hypoglycemia compared to those with a
mean BG of 80 to 110 mg/dL and no hypoglycemia
highlights the different outcomes of Leuven 1 [4] and 2
[6]. In the medical ICU trial [6] the markedly higher
rate of severe hypoglycemia in patients attenuated the
beneficial impact of intensive insulin therapy observed
in the surgical ICU trial [4]. Moreover, while in both
trials, the “conventional” arm had a glycemic target
range of 180 to 200 mg/dL, our investigation demon-
strated that patients with mean BG ≥ 180 mg/dL and no
hypoglycemia sustained even higher mortality than did
those with mean BG of 80 to 110 mg/dL with hypogly-
cemia. Finally, in our study, patients with hypoglycemia
and a mean BG of 80 to 110 mg/dL sustained higher
mortality than did those without hypoglycemia and a
mean BG of 140 to 180 mg/dL, analogous to the conclu-
sions of the NICE to SUGAR trial, in which the 13.6-
fold higher rate of severe hypoglycemia in patients trea-
ted in the interventional arm compared to those in the
control arm was associated with higher mortality [9].
Conclusions
This investigation supports and extends the findings of
other recent studies of the impact of hypoglycemia in
the critically ill and suggests that mild hypoglycemia,
defined as BG < 70 mg/dL, is independently associated
with increased risk of mortality. Of course, it would cer-
tainly be unethical and, therefore, impossible to perform
a randomized trial targeting hypoglycemia in a group of
critically ill patients. However, while causality cannot be
proven by these data - they must be considered hypoth-
esis generating - the findings of this investigation sug-
gest that critical care teams should attempt to avoid
even modest degrees of hypoglycemia in their patients.
Key messages
￿ Mild hypoglycemia, defined as BG < 70 mg/dL,
was associated with increased risk of mortality in a
diverse and heterogeneous group of three patient
cohorts.
￿ The relative risk of mortality associated with hypo-
glycemia differed among the cohorts.
￿ The association of mild hypoglycemia with mortal-
ity was observed in medical and surgical patients, in
diabetics and non to diabetics and it occurred inde-
pendently of mean BG during ICU stay.
￿ The association of mild hypoglycemia with mortal-
ity was strongest in patients with mild to moderate
and moderate to severe disease upon presentation to
the ICU, reflected by APACHE II scores < 15 and
15 to 24, respectively, and was weaker in patients
with APACHE II scores ≥ 25.
￿ Efforts to reduce the occurrence of mild hypogly-
cemia in critically ill patients may reduce mortality.
Additional material
Additional file 1: Stamford Hospital glycemic management protocol.
Additional file 2: GLUCONTROL trial glycemic management
protocols.
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